HomeNewsBusinessMarkets'Good time to invest in firms having longevity, but don't expect returns immediately'

'Good time to invest in firms having longevity, but don't expect returns immediately'

Going forward, equity markets would be a function of economic recovery and sustained liquidity support provided by central banks to support financial markets.

June 16, 2020 / 16:34 IST
Story continues below Advertisement

Every fall is not the same, but similar. It is a good time to pick up businesses having longevity, and ride through this volatility. But, investors cannot expect to reap benefits immediately as markets don't like uncertainty, Hemang Kapasi, Portfolio Manager – Equity Investment Products, Sanctum Wealth Management, said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpt:

Story continues below Advertisement

Q) Indian market snaped two-weeks of positive close and turned negative. What led to the fall on D-Street especially when it started off on a bullish note?

A) If one does an analysis of equity market performance for the last one month, all the major world equity market indices are in positive territory from ~5-15 percent.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show